The global central venous catheter market was valued at USD 1.37 billion in 2024 and is predicted to be worth USD 1.82 billion by 2029, growing at a CAGR of 5.88% from 2024 to 2029.
These diseases require long-term intravenous therapies and treatments. According to a WHO report, cardiovascular diseases were one of the leading causes of death globally in 2019, when around 17.9 million people died from cardiovascular diseases, which comprises 32% of all global deaths. Therefore, the growing need for cardiac surgeries to prevent deaths will lead to an increase in the usage and demand of central venous catheters, thus driving market growth. Central venous catheters are largely used for providing chemotherapy, and other drugs to patients suffering from cancer. As per the data cited by the World Health Organization 2022, around 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.93 million cases of colon and rectum cancer, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in the year 2020. Therefore, the increasing prevalence of cancer is going to positively impact the central venous catheter market in the upcoming years.
The growing geriatric population, increasing investments in R&D activities and rising number of initiatives from various governments to treat people with chronic diseases further fuel the growth rate of the market. The increase in the geriatric population globally is expected to bolster the central venous catheter market as the elderly are more prone to developing chronic diseases, thereby increasing the demand for CVC in the treatment of patients. Continuous advancements in catheter technology have improved the safety, efficacy and convenience of CVCs. Manufacturers have introduced innovations such as antimicrobial coatings, improved materials, and integrated safety features to reduce the risk of infections and other complications associated with CVC use. Technological advancements attract healthcare providers and contribute to market growth. Moreover, the central venous catheters market manufacturers are involved in strategic business expansion activities to enhance their product portfolio and increase their customer base, which will also spur market growth.
The rising number of central venous catheter recalls and infections may act as restraints to the central venous catheter market growth. The use of CVCs carries the risk of complications, including catheter-related bloodstream infections (CRBSIs), thrombosis, mechanical complications, and mispositioning. CVCs are subject to strict regulatory standards and requirements to ensure safety and efficacy. The process of obtaining regulatory approvals and clearances can be time-consuming and costly for manufacturers. Stringent regulatory requirements can create barriers to entry for new market players and impact the market's overall growth.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Product Type, Design, End-user & Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa. |
Based on the product type, the tunneled central venous catheter segment holds the highest share of the central venous catheter market during the forecast period owing to the benefits and applications associated with tunneled central venous catheters. It is a universally applicable device as it can be inserted at multiple sites and is functional in nearly all types of patients. Tunneled central venous catheters can be used to give IV therapy easily and reduce patient discomfort as they are known to be very secure in the vein. The catheter also prevents other complications such as a burning sensation.
Based on the design, the multiple central venous catheter segment accounts for the highest share of the global market during the forecast period.
Based on end-user, the hospitals and clinics segment currently accounts for the major share of the market and is anticipated to remain dominant over the forecast period due to the increasing usage of central venous catheters in ICUs.
Based on geography, North America holds the dominant position in the central venous catheter market in 2023. This can be attributed to the rising prevalence of different cancer types and the increased innovations in the United States. The demand for the central venous catheters market is going to increase during the forecast period owing to the presence of major key players in the market and a large pool of patients.
Asia Pacific is expected to be the fastest-growing market in terms of revenue generation with a CAGR of over 6% over the forecast period, while Europe is also anticipated to exhibit a healthy CAGR despite a decline in population.
Edwards Life Sciences, Angio Dynamics, C.R. Bard, Lepu Medical Technology, Kimal, Terumo Corporation, Vygon (U.K.) Ltd, Becton Dickinson Company, Medrad (Bayer AG), Johnson and Johnson, Rochester Medical Co, B. Braun Melsungen AG, ZOLL Medical Corporation, VOGT Medical, Insung Medical, Cook Group, Teleflex Incorporated, Poly Medicure Ltd., ICU Medical Inc., Medline Industries, Medtronic, Prunus Medical, Merit Medical Systems, SCW Medicath Ltd, Prodimed, Smith Medical and TuoRen are some of the major players in the CVC market.
By Product Type
By Design
By End-User
By Region
Frequently Asked Questions
The global central venous catheter market is expected to grow at a CAGR of 5.88% during the forecast period.
Edwards Life Sciences, Angio Dynamics, C.R. Bard, Lepu Medical Technology, Kimal, Terumo Corporation, Vygon (U.K.) Ltd, Becton Dickinson Company, Medrad (Bayer AG), Johnson and Johnson are some of the key market players in the central venous catheter market
The North American central venous catheter market is expected to grow significantly and hold the largest revenue share during the forecast period.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region